A real licensed daily tablet treatment now exists for weight management in the UK.
Treatment overview
Wegovy Pill UK
The Wegovy pill is now approved in the UK as the first licensed oral GLP-1 weight-loss treatment. The key questions are what has changed, which providers look closest to launch, and whether the tablet option suits real life better than injections.
No weekly injections, but stricter everyday timing and fasting rules while provider rollout is still forming.
What the Wegovy pill changes
The Wegovy pill is now approved in the UK as an oral semaglutide route for weight management. Approval was confirmed on 11 June 2026, with private supply expected from July 2026.
The key question now is simple: how does this licensed tablet treatment compare with the injectable options already on the market?
The practical fit in plain English
Daily tablet
No weekly pen. The pill is taken every morning and may suit people who dislike injections.
Same molecule
It still uses semaglutide, so the main difference is route and administration rather than mechanism.
New provider market
The first useful question is not price alone, but which providers look genuinely ready to supply it.
Morning rules matter
The tablet needs fasting, a small amount of water, and a 30-minute gap before food or other medicines.
UK providers to watch as supply opens
This table is built for launch tracking, with provider rows and pricing fields ready to activate once live stock and stable public routes are confirmed.
| Provider | Type | Current signal | Price from | What to watch |
|---|---|---|---|---|
| Simple Online Pharmacy | Online pharmacy | Strong early public price signal | £129/month | Useful benchmark for starter-stage pricing. |
| Voy | Specialist clinic | Lower-entry price signal on longer plan | From £79/month* | Check how plan length affects the headline. |
| Chemist4U | Online pharmacy | Early July expectation | TBC | Likely to shape the mainstream online-pharmacy offer. |
| Dr Weightmans | Online pharmacy | Mid-July expectation | TBC | Worth watching if second-wave supply matters more than day-one hype. |
| Boots Online Doctor | Retail-backed online doctor | Summer 2026 signal | TBC | Mainstream retail access would change visitor confidence quickly. |
*Quoted on a longer-plan starting-dose basis. Confirm live terms directly when provider routes open.
The oral dose schedule
1.5mg daily
Days 1 to 30. Starting dose used to ease tolerability.
4mg and 9mg daily
Step-up phases across roughly days 31 to 90 as the body adjusts.
25mg daily
Maintenance stage from day 91 onwards.
The biggest practical difference from injections is the routine: after at least 8 hours of fasting, the pill is taken with a small amount of plain water and you wait 30 minutes before food, coffee or other medicines. For some people that will feel easy; for others it will be the main drawback.
Wegovy pill vs Wegovy injection
| Question | Wegovy pill | Wegovy injection |
|---|---|---|
| How it is taken | Daily oral tablet | Weekly subcutaneous injection |
| Main practical advantage | Needle-free and easier for travel or storage | No daily fasting rules |
| Main friction point | Morning administration rules matter | Injection format still puts some people off |
| Clinical benchmark | About 16.6% average weight loss in OASIS 4 | About 17.5% average weight loss in STEP 1 |
Who the pill is most likely to suit
- People who have delayed GLP-1 treatment because they do not want injections.
- People who travel frequently and would prefer not to think about pen storage and weekly injection handling.
- People who still want a licensed obesity-first semaglutide route rather than looser tablet confusion elsewhere in the market.
- People whose prescriber thinks semaglutide remains the right mechanism, but who need a different format.
The main trade-off is convenience versus format. The weekly pen is usually easier once established. The pill feels more approachable up front if needles are the real barrier.
How it compares with the wider market
Wegovy injection
The established semaglutide route and still the cleaner choice for many people who want simplicity once treatment starts.
Mounjaro
The stronger average-outcome injection treatment in trial terms, but not needle-free and not the same active ingredient.
Approval update
The supporting news post covers what the MHRA approval changes in search, routing and provider-language terms.
Questions people ask before provider links go live
Can I buy the Wegovy pill in the UK yet?
Not widely yet. Approval is in place, but broader private supply is still expected from July 2026.
Will it replace the Wegovy injection?
No. It adds another semaglutide route, but the weekly pen will still suit plenty of patients once treatment is underway.
Will it be cheaper than Mounjaro or injectable Wegovy?
Early starter-dose pricing look competitive, but the real answer depends on maintenance pricing, plan structure and bundled support.
Treatment next step
Move from treatment research into the provider shortlist
Treatment pages attract strong intent, but the useful next step is usually the clinic comparison, provider evidence and a broader look at how treatments differ in practice.
Common questions
Can this site tell me which treatment is suitable?
No. The site can help you compare routes and questions to ask, but suitability depends on clinical assessment by a regulated provider.
Why does the parent site link to Wego and Jaro?
The parent site covers broad route decisions. Wego and Jaro remain the specialist sites for deeper Wegovy and Mounjaro provider detail.
Are prices fixed?
No. Prices, delivery costs, offer terms, eligibility and availability can change. Always confirm current information directly with the provider.
Does the site sell medicines?
No. It is informational and comparison-led. It does not sell, prescribe or supply prescription-only medicines.